[
  {
    "ts": null,
    "headline": "Will AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth?",
    "summary": "ABBV's expanding neuroscience portfolio, led by Botox, Vraylar and new launches like Vyalev, continues to fuel top-line growth.",
    "url": "https://finnhub.io/api/news?id=af41cf519e3e52d121a28bf7418c92a9d4791bec6c84aed8ec79b7ab8e2ce6d6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756995420,
      "headline": "Will AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth?",
      "id": 136641801,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ABBV's expanding neuroscience portfolio, led by Botox, Vraylar and new launches like Vyalev, continues to fuel top-line growth.",
      "url": "https://finnhub.io/api/news?id=af41cf519e3e52d121a28bf7418c92a9d4791bec6c84aed8ec79b7ab8e2ce6d6"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie and Genmab’s Epkinly shows outpatient viability in Phase II trial",
    "summary": "According to experts, the ability to dose Epkinly in the outpatient setting could provide broader access to the drug.",
    "url": "https://finnhub.io/api/news?id=b9e000b87a3f145006492888896171eee5103d23a853a7f0aa672ffcd658cc86",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756986062,
      "headline": "AbbVie and Genmab’s Epkinly shows outpatient viability in Phase II trial",
      "id": 136641843,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "According to experts, the ability to dose Epkinly in the outpatient setting could provide broader access to the drug.",
      "url": "https://finnhub.io/api/news?id=b9e000b87a3f145006492888896171eee5103d23a853a7f0aa672ffcd658cc86"
    }
  },
  {
    "ts": null,
    "headline": "Anti-Parkinson's Drugs Global Market Research Report 2025-2030 | $9.2 Bn Opportunities Driven by Increased Awareness in Emerging Countries and a Robust Pipeline of Innovations",
    "summary": "Explore the global anti-Parkinson's drugs market with our report, analyzing trends, revenue projections, and CAGRs from 2024 to 2030. Segmented by drug class and region, the study covers market dynamics, ESG impacts, and competitive analyses of key players like AbbVie and Teva. Discover emerging technologies and growth strategies shaping this evolving sector. Global Anti-Parkinson’s Drugs Market Global Anti-Parkinson’s Drugs Market Dublin, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The \"Anti-Parkinson's",
    "url": "https://finnhub.io/api/news?id=8ecadd67ca710229da31e56a0ad88dd3bfae30872c698e555a10ef99503ac19d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756982760,
      "headline": "Anti-Parkinson's Drugs Global Market Research Report 2025-2030 | $9.2 Bn Opportunities Driven by Increased Awareness in Emerging Countries and a Robust Pipeline of Innovations",
      "id": 136641844,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Explore the global anti-Parkinson's drugs market with our report, analyzing trends, revenue projections, and CAGRs from 2024 to 2030. Segmented by drug class and region, the study covers market dynamics, ESG impacts, and competitive analyses of key players like AbbVie and Teva. Discover emerging technologies and growth strategies shaping this evolving sector. Global Anti-Parkinson’s Drugs Market Global Anti-Parkinson’s Drugs Market Dublin, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The \"Anti-Parkinson's",
      "url": "https://finnhub.io/api/news?id=8ecadd67ca710229da31e56a0ad88dd3bfae30872c698e555a10ef99503ac19d"
    }
  },
  {
    "ts": null,
    "headline": "Health Canada approves AbbVie’s Elahere for ovarian cancer",
    "summary": "The approval was based on outcomes from the randomised MIRASOL Phase III trial.",
    "url": "https://finnhub.io/api/news?id=7e78a2c066a3c4c7ac2c019f0afa9d5f93c5c72ccc9ddaeb7c546d6495cfe717",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756980313,
      "headline": "Health Canada approves AbbVie’s Elahere for ovarian cancer",
      "id": 136641845,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The approval was based on outcomes from the randomised MIRASOL Phase III trial.",
      "url": "https://finnhub.io/api/news?id=7e78a2c066a3c4c7ac2c019f0afa9d5f93c5c72ccc9ddaeb7c546d6495cfe717"
    }
  },
  {
    "ts": null,
    "headline": "Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years?",
    "summary": "There is more to like than the dividend with these companies.",
    "url": "https://finnhub.io/api/news?id=2ec085e7fd47269aacd4a66e5057f6c9f5ee57297e2bf861174fbcf85abcc7d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756976940,
      "headline": "Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years?",
      "id": 136641804,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "There is more to like than the dividend with these companies.",
      "url": "https://finnhub.io/api/news?id=2ec085e7fd47269aacd4a66e5057f6c9f5ee57297e2bf861174fbcf85abcc7d7"
    }
  }
]